Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug

MT Newswires Live10-08

Sino Biopharmaceutical (HKG:1177) subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's (HKG:2496) cancer drug in mainland China.

The drug M701 is indicated for the treatment of malignant pleural effusion (MPE) and malignant ascites (MA) caused by tumors. It is in stage 3 clinical trials and has shown good results by inciting the immune system to kill cancer cells in abdominal and chest cavities.

Chia Tai will pay 315 million yuan upfront, plus up to 700 million yuan in sales milestone payments, and tiered royalties to YZY Biopharma, a Tuesday Hong Kong bourse filing said.

The pharmaceutical company's shares closed nearly 7% lower on Tuesday.

Price (HKD): $3.85, Change: $-0.28, Percent Change: -6.78%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473444417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473444417","market":"hk","top_or_hot":-1,"title":"Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical (HKG:1177) subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's (HKG:2496) cancer drug in mainland China.</p><p>The drug M701 is indicated for the treatment of malignant pleural effusion (MPE) and malignant ascites (MA) caused by tumors. It is in stage 3 clinical trials and has shown good results by inciting the immune system to kill cancer cells in abdominal and chest cavities.</p><p>Chia Tai will pay 315 million yuan upfront, plus up to 700 million yuan in sales milestone payments, and tiered royalties to YZY Biopharma, a Tuesday Hong Kong bourse filing said.</p><p>The pharmaceutical company's shares closed nearly 7% lower on Tuesday.</p><p>Price (HKD): $3.85, Change: $-0.28, Percent Change: -6.78%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 16:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (HKG:1177) subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02496","symbol_name":"友芝友生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473444417","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473444417","pubTimestamp":1728376423,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's  cancer drug in mainland China.The drug M701 is indicated for the treatment of malignant pleural effusion  and malignant ascites  caused by tumors. It is in stage 3 clinical trials and has shown good results by inciting the immune system to kill cancer cells in abdominal and chest cavities.Chia Tai will pay 315 million yuan upfront, plus up to 700 million yuan in sales milestone payments, and tiered royalties to YZY Biopharma, a Tuesday Hong Kong bourse filing said.The pharmaceutical company's shares closed nearly 7% lower on Tuesday.Price : $3.85, Change: $-0.28, Percent Change: -6.78%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02496":"友芝友生物-B","BK1515":"抗疫概念","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK1589":"北水核心资产","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4585":"ETF&股票定投概念","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4227":"交易和支付处理服务","BK4566":"资本集团","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0109392836.USD":"富兰克林科技股A","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","BK4535":"淡马锡持仓","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","BK4527":"明星科技股","BK4559":"巴菲特持仓","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4526":"热门中概股","BK4588":"碎股","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","BK1161":"生物科技","MA":"万事达","01177":"中国生物制药","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0289941410.SGD":"AB FCP I Dynamic Diversified AX SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","BK4023":"应用软件","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD"},"translate_title":"中国生物制药子公司获得YZY Bio癌症药物的中国许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MA":1,"02496":0.9,"01177":0.9},"content_text":"Sino Biopharmaceutical (HKG:1177) subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's (HKG:2496) cancer drug in mainland China.The drug M701 is indicated for the treatment of malignant pleural effusion (MPE) and malignant ascites (MA) caused by tumors. It is in stage 3 clinical trials and has shown good results by inciting the immune system to kill cancer cells in abdominal and chest cavities.Chia Tai will pay 315 million yuan upfront, plus up to 700 million yuan in sales milestone payments, and tiered royalties to YZY Biopharma, a Tuesday Hong Kong bourse filing said.The pharmaceutical company's shares closed nearly 7% lower on Tuesday.Price (HKD): $3.85, Change: $-0.28, Percent Change: -6.78%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473444417"}